A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study

作者：Horton Terzah M^*; Drachtman Richard A; Chen Lu; Cole Peter D; McCarten Kathleen; Voss Stephan; Guillerman Robert P; Buxton Allen; Howard Scott C; Hogan Shirley M; Sheehan Andrea M; Lopez Terrada Dolores; Mrazek Matthew D; Agrawal Neeraj; Wu Meng Fen; Liu Hao; De Alarcon Pedro A; Trippet Tanya M; Schwartz Cindy L

来源：British Journal of Haematology, 2015, 170(1): 118-122.

DOI：10.1111/bjh.13388

• clinical trials
• paediatric oncology
• childhood haematological malignancies
• NF-kappa B

A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p=032). Although not statistically different, results suggest IVB may be a promising combination.

• 出版日期2015-7